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Background: There is promising but conflicting evidence to recommend the addition of probiotics to foods for
prevention and treatment of allergy. Based on previous studies with fermented milk containing Lactobacillus
paracasei NCC2461, we aimed to compare the effect of a powder form of the latter probiotic with the effect of a blend
of Lactobacillus acidophilus ATCC SD5221 and Bifidobacterium lactis ATCC SD5219 in patients with allergic rhinitis.
Methods: A double-blind, randomized, cross-over study, involving 31 adults with allergic rhinitis to grass pollen, was
performed outside the grass pollen season (registration number: NCT01233154). Subjects received each product for
4-weeks in two phases separated by a wash-out period of 6 to 8 weeks. A nasal provocation test was performed before
and after each 4-week product intake period, and outcome parameters (objective and subjective clinical symptoms;
immune parameters) were measured during and/or 24 hours after the test.
Results: Out of the 31 subject enrolled, 28 completed the study. While no effect was observed on nasal congestion
(primary outcome), treatment with NCC2461 significantly decreased nasal pruritus (determined by VAS), and leukocytes
in nasal fluid samples, enhanced IL-5, IL-13 and IL-10 production by peripheral blood mononuclear cells in an allergen
specific manner and tended to decrease IL-5 secretion in nasal fluid, in contrast to treatment with the blend of
L. acidophilus and B. lactis.
Conclusions: Despite short-term consumption, NCC2461 was able to reduce subjective nasal pruritus while not
affecting nasal congestion in adults suffering from grass pollen allergic rhinitis. The associated decrease in nasal
fluid leukocytes and IL-5 secretion, and the enhanced IL-10 secretion in an allergen specific manner may partly
explain the decrease in nasal pruritus. However, somewhat unexpected systemic immune changes were also
noted. These data support the study of NCC2461 consumption in a seasonal clinical trial to further demonstrate
its potentially beneficial effect.
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Current available treatments for allergic rhinitis are not
devoid of side-effects and primary prevention strategies
are non-existent. This has led to the search for new
approaches to prevent or reduce allergic symptoms and
improve quality of life of patients. In this context, and
regarding its safety profile, interest in nutritional inter-
vention for allergy management has been growing.
Recent scientific evidence from pre-clinical studies
and human clinical trials has highlighted different
nutritional interventions such as vitamins, lipids, diet-
ary polyphenols and probiotics as promising agents
that can impact both allergic sensitization and allevi-
ate allergic symptoms [1-3]. Probiotics are defined as
“live microorganisms which when administered in
adequate amounts confer a health benefit on the host”
[4]. The “hygiene hypothesis” suggested that modern
living conditions may have affected the initial estab-
lishment of the intestinal microbiota, with subsequent
impact on the development of the GALT (gut-asso-
ciated lymphoid tissue) at an early age, and therefore
on the regulation of local and systemic immune
responses [5]. In addition, several studies pointed out
differences in the gut microbial composition between
infants developing allergy or not, suggesting a crucial
role of the intestinal microbiota on the immune system
orientation [6-9].
Most clinical studies in the field of probiotics and
allergy have focused on the prevention or treatment
of atopic dermatitis, with divergent outcomes likely
resulting from different probiotic strains, target popu-
lations, and study designs [10-15]. Although evidence
of a beneficial effect of probiotics on allergic respira-
tory symptoms is still conflicting [16,17], a few studies
conducted in children and adults with allergic rhinitis
suggested a beneficial effect of the consumption of
specific probiotic strains belonging to the Lactobacillus
casei, Bifidobacterium longum, Bifidobacterium lactis or
Lactobacillus paracasei species [18-22]. We also recently
showed in a crossover, placebo controlled clinical trial
that the administration of a fermented milk containing
Lactobacillus paracasei NCC2461 yielded encouraging
results on allergic rhinitis symptoms and immune bio-
markers [23]. To reinforce our previous observations
on Lactobacillus paracasei NCC2461, we conducted
the present study to compare the effect of a 4-week
consumption of two probiotic preparations on clinical
and biological responses to a well-reproducible nasal
provocation test (NPT) with grass pollen, in adult vol-
unteers with grass pollen allergic rhinitis. The second
probiotic preparation (combination of L. acidophilus
SD5221 and B. lactis SD5219) was chosen based on
promising results obtained in children with birch pollen
allergy [24].Material and methods
Population
Thirty-one adult volunteers with a history of grass pollen
allergic rhinitis were enrolled (Figure 1) in a single center
study (CHUV, Lausanne, Switzerland) on the basis of
the following inclusion criteria: (1) age between 18 and
35 years; (2) a history of allergic rhinitis during the latest
grass pollen season confirmed by positive skin prick
test (SPT) to grass pollen (wheal diameter > 3 mm); and (3)
a positive response to a NPT with grass pollen (combined
nasal reaction threshold ≤ 10′000 standardized quality
units (SQs)/ml grass pollen or less at the screening/
inclusion phase). Volunteers were excluded from the
study when presenting any medical condition that
could influence the study (pregnancy, viral or bacterial
airway infection, active allergic rhinitis), or uncontrolled
asthma (peak expiratory flow < 20% of volunteer’s best
personal value), when treated with antihistamine or
antibiotics less than two weeks before enrolment or
during the trial. Furthermore they were also excluded
when presenting with allergic rhinitis to tree pollen or
perennial allergic rhinitis. Clinical research protocol was
approved by the Ethical Review Board of the Faculty of
Biology and Medicine, Lausanne (N° 153/07) as well as
by Swiss Regulatory Authorities (Swissmedic, Bern) and
all enrolled subjects provided informed consent before
the start of the study.
Study products
Powder sachets contained maltodextrin and probiotics
(≈ 1010 colony forming unit (cfu) each), either L. paracasei
NCC2461 (CNCM I-2116; ST11; Nestlé, Switzerland)
or a blend (1:3) of L. acidophilus ATCC SD5221 and B.
lactis ATCC SD5219 (Danisco Cultures, USA). They
were kept at 4°C until consumption. The 31 subjects
were randomized according to a computer generated
allocation schedule to receive one of the individually
coloured test products and instructed to dilute once a
day the content of one sachet into 2 dl of cold milk just
before consumption on an empty stomach. Quality
control of the powder sachets was carried out for product
release, in the middle, and at the end of the study, to
ensure viability of the tested probiotics.
Study protocol
The study was designed as a randomized, double-blind,
two-treatment, cross-over clinical trial, performed out-
side of the grass pollen season (between August 2007
and March 2008; registration number: NCT01233154) to
evaluate the effect of a 4-week consumption of two
probiotic formulations (period A and period C) on clinical
and biological responses to NPT (Figure 2). Both inves-
tigators and subjects were aware that the aim of the
study was to test two different probiotic preparations, but
Assessed for eligibility (n= 35)
Randomized (n= 31)
Excluded (n=4)
• Not meeting inclusion criteria (n=3)
• Declined to participate (n=1)
Allocated to sequence
NCC 2461      ATCC SD5221/SD5219 (n=15)
• Received allocated treatments (n=15)
• Did not receive allocated treatments (n=0)
Allocated to sequence
ATCC SD5221/SD5219      NCC2461 (n=16)
• Received allocated treatments (n=14)
• Did not receive the second treatment due to the 
beginning of the grass pollen season (n=2)
Analyzed (n=15)
• Excluded from the ITT analysis (n=0)
Analyzed (n=16)
• Excluded from the ITT analysis (n=3) due to 
non consumption of second treatment (n=2) 
and no data for primary outcome in the first 
period (n=1)
Figure 1 Participants’ recruitment and inclusion flow chart.
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preparation. The choice of the duration (four weeks) of
the treatment period was mainly based on the encouraging
results obtained with L. paracasei NCC2461 in a previous
clinical trial [23]. Products were supplied before each
period of product consumption. Both treatment periods
were separated by a wash-out period (period B) of six
to eight weeks. A NPT was performed before and after
each treatment period, and outcome parameters were
measured during and/or 24 hours after each NPT. Non
solicited adverse events were recorded all along the
trial. Compliance was evaluated on subjects’ product
consumption reported in diary cards and from stool
samples analysis of studied probiotics at the beginning
and the end of each treatment period.
The primary outcome of the study was defined as the
difference before and after treatment with each probiotic
preparation on subjective nasal congestion by visual
analogical scale (VAS). We additionally compared the
two treatments in their capacity to modify this endpoint.
Secondary endpoints included 1) differences before and
after treatment in allergen dose levels necessary to reachPeriod B: 6-8 w
Wash-out
Period A: 4 weeks
(Product A / Product B consumption)
NPT1
Info
SPT Feces Feces
NPT2
consumption )
Screening / Inclusion
and blood sampling and blood sampl
Figure 2 Study design. NPT: nasal provocation test; SPT: skin prick test; Inthe combined reaction threshold. Each clinical criterion
and their respective thresholds were also examined separ-
ately as secondary endpoints and compared between the
two treatment arms; 2) nasal pruritus evaluated by VAS as
well as immune markers from blood and nasal samples as
described below.
NPT and clinical assessment
The NPT was performed as described previously [25-27],
before and after each 4-week product intake period. The
“combined nasal reaction threshold” was defined as the
dose level of the allergen extract for which at least two of
the three following clinical criteria were fulfilled: (1) ≥ 5
sneezes in first ten minutes after challenge; (2) ≥ 0.5 g nasal
secretion in the first ten minutes after challenge (above
diluent value); (3) a decrease in peak nasal inspiratory flow
(PNIF) ≥ 40% or minimal cross-sectional area (MCA) ≥ 30%
of baseline (diluent value), whichever came first [28].
Nasal samples and immune markers
Nasal samples were collected before NPT, 10 min. after
the 1′000 SQ/ml challenge and 24 h after NPT: cellseeks Period C: 4 weeks
(Product B / Product A consumption)
NPT3 NPT4
consumption )
ing Feces and blood sampling Feces and blood sampling
fo: information to subject.
Table 1 Demographic data at enrolment
n Mean SD Min Max
Age (years) 31 26.8 3.7 20.2 34.6
Height (cm) 31 173.8 7.3 161.0 190.0
Weight (kg) 31 69.7 12.5 49.0 98.0
Body mass index (BMI, kg/m2) 31 22.97 3.25 17.36 30.93
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septum of a single nostril three times with an endocervical
sampling brush (cyto-brosse, Charles Berdat, Switzerland)
as previously described [19], and fluids by application of 2
filter paper strips (6×30 mm, Whatman N° 903, Whatman
Paper Ltd., Maidstone, UK) in the controlateral nostril
(inferior turbinate and nasal septum) for 10 min [29]. After
removal, the strips were placed in a 2 ml silicone-coated
tube in dry-ice and stored at −80°C until processed. Papers
were eluted in 1 ml of Tris buffer 0.1 M, pH 7.4, 0.002%
Tween 20 by strong agitation at 4°C during at least 2 h
[30]. Cytokines (IL-5 and TNFα) were measured in nasal
fluid by multiplexed bead-based flow cytometry (Fluorokine
multiplex kit, R&D Systems, Inc, Minneapolis, USA)
using a Luminex 100 analyser (detection limits: 0.21
and 0.59 pg/ml respectively) [23].
Blood samples and immune markers
Serum samples (10 ml) for measuring specific IgE and
IgG4 levels to grass pollen, were collected 24 h after
NPT, before and after each product consumption period
(Figure 2) and stored at −80°C until analysis. Specific IgG4
and IgE were measured by the CAP System (UniCAP
100, Pharmacia Diagnostics, Uppsala, Sweden). For the
in vitro stimulation of peripheral blood mononuclear
cells (PBMCs), whole blood was collected 24 h after
NPT (before and after each product consumption period),
in sodium citrate tubes (Vacutainer® CPT™, BD, Basel,
Switzerland), and PBMCs purified by centrifugation
over a density gradient. After washing, PBMCs were
stored in liquid nitrogen until use. PBMCs were thawed,
and cultured at 2×106 cell/ml as previously described [23]
in the presence of 90 μg/ml of grass pollen extract (ALK
Wässrig SQ; ALK-Abello, Hørsholm, DK), or a cocktail
of vaccine antigens (5 μl/ml Candida mannan (NIBSC,
London, UK), 10 μg/ml tetanus toxoid, 5 μg/ml Tuberculin
Purified Protein derivative (PPD, SSI, Copenhagen, DK)), or
medium alone. The supernatants were collected after 6
days of culture, and stored at −20°C until evaluation of their
cytokine contents (IL-5, IL-8, IL-10 and IFNγ by multiplex
flow cytometry as described above and IL-13 by ELISA
(Diaclone, Besançon, F); detection limits: 0.21, 0.50, 0.34,
1.28 and 0.8 pg/ml respectively).
Fecal samples
Fecal samples were collected as described in Figure 2 into
sterile tubes maintained in anaerobic conditions using the
AnaeroGen system (Oxoid, UK) and kept at <10°C until
processing within 12 hours. Briefly, 100 mg of faeces
sample were resuspended in sterile saline and serial
dilutions performed (10-2-10-6). Then, 100 μL of each
dilution were plated on MRS and BSM media [31]. Plates
were incubated at 37°C in anaerobic conditions. After
48 h, the whole bacteria lawn was scraped off, resuspendedin 10 μL of NaCl 0.9% and centrifuged for 3 min at
5000 rpm. The pellet was dissolved in 1 mL NaCl 0.9%
and the DNA was extracted by mechanical disruption
(bead-beater) to perform PCR using strain (L. paracasei
NCC2461 and L. acidophilus ATCC SD5221) or cluster of
strains (B. lactis ATCC SD5219) specific primers. Results
were expressed as presence or absence of the bacterial
strains in the samples.
Statistical analysis
Demographic and baseline characteristics were documented
by descriptive statistics. According to a previous study,
knowing that the within subject SD on the primary out-
come was 0.6, a sample size of 27 subjects allows to
predict a difference of 0.3 (VAS scale) with a power of
80% and a type I error of 0.05 [23]. Taking into account
a drop-out rate of 15%, 32 subjects were planned to be
enrolled. Comparison of primary outcome parameters
before and after each probiotic treatment was analyzed
with Wilcoxon Signed-Rank Test for each of the products
tested. For each treatment, the comparisons of scores
between post- and pre-treatment phases were analyzed
by linear mixed model with phase, allergen concentration
and period as fixed effects and subjects as random effect.
For each treatment, the comparisons of the number of
subjects for reaction thresholds between post- and pre-
treatment phases were estimated by Cochran-Mantel-
Haenszel statistics based on table thresholds with the
hypothesis that mean thresholds differ. Immunological
data were analyzed by Wilcoxon Signed-Rank Test or
Paired t-Test according to normality of data. The same
analyses were performed on the “post-treatment minus
pre-treatment” differences for all outcome parameters,
when comparing the two probiotic preparations. All statis-
tical analyses were done with SAS software (version 9.1).
Results
Demographic and baseline data
Thirty-one patients (21 males and 10 females) aged 18 to
35 years were enrolled into the study (Table 1; Figure 1).
All the results concerning these subjects constituted the
intention-to-treat (ITT) data set. Twenty-three percent of
enrolled subjects were smokers, with an average of 6 ± 3
cigarettes per day. Later enrolment of two subjects led to
their exclusion from participating in the second treatment
period, because of the overlap of the second period of
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subject, the primary outcome parameter was not evaluated
in the first treatment period. Therefore, twenty-eight
subjects completed the study.
Compliance and safety
Compliance with product consumption was good all over
the study. According to diary cards, the mean duration
of consumption of L. paracasei NCC2461 and blend of
L. acidophilus ATCC SD5221 and B. lactis ATCC SD5219
were 28.4 ± 0.4 and 31.1 ± 0.4 days, respectively. Con-
sumption of both probiotic preparations was confirmed
by their respective presence in the subject’s feces after
period A and C (Table 2). Importantly, the wash-out
period duration was considered to be well-adapted con-
sidering the absence of strain detection at the end of
the wash-out period (“Before period C” column) in all
except 2 volunteers. For patient 29, the detection of L.
paracasei NCC2461 is probably a false positive result,
since this strain was not detected before the wash-out
period. For patient 32, we suspect that other Bifidobac-
terium spp strain(s), closely related to B. lactis ATCC
SD5219, could have been detected because of the use
of species and not strain related primers. There was no
noticeable clinical issue and no formulation-related
adverse event during the study.
Clinical outcomes
With regards to the primary outcome, there was no
significant difference at all grass pollen concentrations
between the post-treatment and the pre-treatment
scores for both probiotic products on nasal congestion
scores (as determined by VAS, Figure 3). Furthermore,
neither of the two probiotic treatments significantly
affected the objective clinical parameters (PNIF, MCA,
nasal secretions, sneezes, and the combined nasal reaction
threshold). However, subjective nasal pruritus (as deter-
mined by VAS), one of the main secondary outcomes, was
globally significantly lower after L. paracasei NCC2461
treatment than before (ITT analysis; p = 0.005) (Figure 4A)
in contrast to the blend of L. acidophilus ATCC SD5221
and B. lactis ATCC SD5219 which had no effect on nasal
pruritus scores (Figure 4B). Moreover, when the difference
between post-treatment and pre-treatment pruritus
scores was compared between both products, a signifi-
cantly greater reduction in pruritus score was shown
with L. paracasei NCC2461 treatment, as compared to the
L. acidophilus and B. lactis blend (ITT analysis: p = 0.005)
(Figure 4C).
Nasal cell counts and immune markers
Interestingly, after treatment with L. paracasei NCC2461,
the percentage of total leukocytes 24 hours after NPT
was significantly lower than in the pre-treatment phase(p = 0.009; ITT analysis) (Figure 5A). However, the post-
treatment minus pre-treatment difference in leukocyte
percentage did not significantly differ between treatments.
No significant effect on relative nasal cell counts resulted
from treatment with the blend of L. acidophilus ATCC
SD5221 and B. lactis ATCC SD5219 (Figure 5B).
In the L. paracasei treatment arm, the post-treatment
nasal fluid TNFα contents were not significantly different
from the pre-treatment ones (0.028 ± 0.106 pg/ml, p= 0.55),
a trend was observed toward a decrease in IL-5 measured
24 hours after NPT (−0.756 ± 1.412, p= 0.08; ITT analysis).
No effect of treatment with the blend of L. acidophilus
and B. lactis was observed on nasal fluid cytokine levels
of IL-5 and TNF-α (data not shown). The comparison
of the post- minus pre-treatment difference in nasal
fluid cytokine contents between the two treatments did
not show significant differences for IL-5 or TNF-α.
Cell mediated immunity markers
None of the probiotic treatment induced any change in
the spontaneous secretion by PBMC (Table 3; NS). This
suggests that both probiotic treatments are safe and do
not affect the immune system steady state. Treatment with
L. paracasei NCC2461 was associated with a significant
increase in the secretion of IL-5, IL-8, IL-10 and IL-13
by grass pollen-stimulated PBMCs, while no effect on
IFN-γ secretion was observed (Table 3). In contrast,
treatment with the blend of L. acidophilus ATCC SD5221
and B. lactis ATCC SD5219 did not result in differences in
cytokine secretion by grass pollen-stimulated PBMCs
(Table 3). Comparison of cytokine changes between both
treatments did not show significant differences for IL-5,
IL-10, IL-13, and IFN-γ secretion by grass pollen-
stimulated PBMCs, whereas IL-8 secretion was signifi-
cantly enhanced with L. paracasei NCC2461 treatment,
as compared to the other treatment (p = 0.03; ITT) (data
not shown).
Treatment with L. paracasei NCC2461 was also asso-
ciated with a significant increase in IL-10 secretion by
PBMCs stimulated by a mix of recall vaccine antigens
(p = 0.01; ITT) (Table 3), whereas the other treatment
did not have such an effect. A significant difference be-
tween both treatments was found for IL-10 secretion
with higher levels obtained after L. paracasei NCC2461
treatment (p = 0.008; ITT) (data not shown).
Serological immune markers
Serum anti-grass pollen specific IgE were significantly
increased after both treatments (56.9 ± 11.6 KU/L and
64.6 ± 12.4 KU/L, mean ± SEM) before and after L. para-
casei NCC2461 treatment, respectively (p = 0.02) and
63.6 ± 12.6 KU/L and 66.3 ± 12.4 KU/L before and after L.
acidophilus ATCC SD5221 and B. lactis ATCC SD5219
treatment, respectively (p = 0.04). No change in specific
Table 2 Detection of L. paracasei NCC2461 and B. lactis SD5219 strains during clinical trial phases (before and after
periods A and C)
Before period A After period A Before period C After period C
Subject study number A B A B A B A B
1 ✓ ✓ ✓
3 ✓ ✓
4 ✓ ✓ ✓
5 ✓
6 ✓ ✓
7 ✓ ✓
8 ✓ ✓
9 ✓ ✓ ✓
10 ✓ ✓
11 ✓ ✓
12 ✓ ✓ ✓
13 ✓
14 ✓
15 ✓ ✓
16 ✓ ✓
17 ✓ ✓
18 ✓ ✓
19 ✓ ✓
20 NS NS
21 ✓ ✓ ✓
22 ✓ ✓
23 ✓ ✓
24 ✓ ✓
26 ✓ ✓
29 ✓ ✓ ✓
30 ✓ ✓
31 ✓ ✓ ✓
32 ✓ ✓
33 ✓ ✓ ✓
34 ✓ NS NS NS NS
35 ✓ NS NS NS NS
✓means that the strain was detected in the faeces of the subject, NS means “no sample available” and A and B correspond to L. paracasei NCC2461 and B. lactis
SD5219, respectively.
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tics and no difference on this parameter was observed
between the two probiotic treatments (data not shown).
Discussion
This study aimed at assessing the effect of two probiotic
preparations on established allergic rhinitis in the frame of
a well-reproducible and well-standardized nasal provoca-
tion test (NPT). The L. paracasei NCC2461 strain was
selected on the basis of preclinical in vivo data. NCC2461
mono-associated germ-free mice developed a TH1-likeserum immunoglobulin profile (increased L. paracasei-spe-
cific IgG2a level as compared to specific IgG1 level) [32]. A
beneficial effect of orally administered L. paracasei strain
NCC2461 was established in a mouse model of asthma
[33] and more importantly, a first pilot proof of efficacy
with L. paracasei strain NCC2461 was obtained in volun-
teers suffering from allergic rhinitis that showed signifi-
cant improvement in nasal congestion and modulation
of immune biomarkers [23]. The combination of 25% L.
acidophilus ATCC SD5221 and 75% B. lactis ATCC
SD5219 was tested in the same setting, based on its
Global effect p=0.19
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Allergen concentration
Pre-treatment Post-treatment
Solvent         100            300             1000           3300         10000           33000            BU
8
7
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5
4
3
2
1
0
Allergen concentration
Pre-treatment Post-treatment
Global effect p=0.33
Solvent         100            300             1000           3300        10000           33000            BU
Allergen concentration
Blend of SD5221 and SD5219
NCC2461 
0.6
0.4
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0
-0.2
-0.4
-0.6
-0.8
-1
Global effect p=0.11
A
B
C
Figure 3 Mean VAS nasal congestion scores according to the allergen dose level (mean ± SEM) pre- and post-treatment with L.
paracasei NCC2461 (A), with the blend of L. acidophilus SD5221 and B. lactis SD5219 (B), and pre- minus post-treatment difference
between the blend of L. acidophilus SD5221 and B. lactis SD5219 (open bars) and L. paracasei NCC2461 (black bars) treatments (ITT
analysis) (C).
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in a PBMC model (personal communication). Moreover
a study recently conducted in children with birch pollen
allergy showed that a 4 month-consumption of the pro-
biotic mix, starting before the onset of the birch pollen
season and continuing during the pollen season, tended
to alleviate allergic rhinitis symptoms, and significantly
prevented pollen-induced eosinophil infiltration in the
nasal mucosa [24].
Although in the present study no significant effect was
observed on the primary outcome i.e. nasal congestion,
treatment with L. paracasei NCC2461 positively modu-
lated several secondary endpoints: it significantly improveda key subjective clinical feature of allergic rhinitis, nasal
pruritus, significantly decreased the percentage of leuko-
cytes in nasal fluid, enhanced allergen specific IL-10 secre-
tion by PBMC and tended to decrease IL-5 in the nasal
fluid, both biological effects supporting the improvement
in nasal pruritus. An increase in IL-5, IL-13, IL-10 and
IL-8 by grass pollen stimulated PBMCs was interestingly
observed after the L. paracasei NCC2461 treatment. Actu-
ally, it is well demonstrated that the induction of IL-10 is
dependent on prior activation of TH2 cytokines [34].
These increases are thus not unexpected. The TH2 type of
cytokine response induced by NCC2461 treatment on
grass pollen stimulated PBMC, further supported by the
A0
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6
Solvent 100 300 1000 3300 10000 33000
Pre-treatment Post-treatment
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Figure 4 Mean VAS pruritus scores according to the allergen dose level (mean ± SEM) pre- and post-treatment with L. paracasei
NCC2461 (A), with the blend of L. acidophilus SD5221 and B. lactis SD5219 (B), and pre- minus post-treatment difference between the
blend of L. acidophilus SD5221 and B. lactis SD5219 (open bars) and L. paracasei NCC2461 (black bars) treatments (ITT analysis) (C).
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non relevant) increase in grass pollen specific IgE, may
be surprising at first glance. Yet, this TH2 profile was
not observed in the induction site, i.e. the nasal mucosa,
and strictly concerned the systemic response. Interestingly,Marschan et al. also described an elevation of plasma IgE
and IL-10 in infants with a family history of allergy. Infants
were given probiotics for 6 months after delivery from a
mother having received the same probiotics for 1 month
before delivery [35].
AB Leukocytes Eosinophils Neutrophils
p=0.009
Leukocytes Eosinophils Neutrophils
Figure 5 Difference on leukocyte percentages (mean ± SEM) post- minus pre- treatment with L. paracasei NCC2461 (A) and with the
blend of L. acidophilus SD5221 and B. lactis SD5219 (B); cells were quantified in nasal fluid 24 h after NPT.
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blend of L. acidophilus ATCC SD5221 and B. lactis ATCC
SD5219 used as comparator for improvement of nasal
pruritus, allergen specific IL-8 and IL-10 secretion by
PBMC after stimulation with allergen and recall antigen,
respectively. Of note, objective clinical parameters deter-
mined during NPT were not improved by this treatment,
reflecting their lower sensitivity, as compared to the VAS
evaluation.
As compared to other studies where probiotics were
administered [36], the treatment period in the present
clinical trial was of relatively short duration. We showed
in a recent study [22] that the duration of the probiotic
treatment may have an impact on the beneficial effect
on both symptoms and immune markers. The beneficial
results obtained on several parameters with L. paracasei
NCC2461 after only 4 weeks of treatment can thus be
considered as encouraging. Moreover, the level of im-
provement of nasal pruritus observed in this study afterL. paracasei NCC2461 consumption was comparable to
the improvement observed after treatment with the anti-
H1 desloratadine [25] and is then likely to have a real
clinical significance. We have also previously reported
an effect of the L. paracasei NCC2461 strain in a cross-
over, placebo controlled trial where the effect was more
pronounced on nasal congestion with the same duration
of treatment. i.e. four weeks. Apart from the different
study design, a possible reason for the different effects can
be accounted to the complexity of allergic rhinitis as a
disease and the fact that not every subject suffering
from allergic rhinitis will manifest with the same pre-
dominant nasal allergy symptom.
Treatment with the blend of L. acidophilus ATCC
SD5221 and B. lactis ATCC SD5219 was not able to in-
duce comparable benefits, although it tended to reduce
nasal symptoms in a different study setting; albeit only
with a longer duration (4 months) of administration [24].
The discrepancy between the two studies with this
Table 3 Difference in cytokine secretion by ex vivo restimulated PBMC isolated from subjects post- minus
pre-consumption of either L. paracasei NCC2461 or a blend of L. acidophilus SD5221 and B. lactis SD5219
L. paracasei NCC2461 treatment
Allergen n n Median Rob. SD SE median Min. Max. p-value
IL5 (pg/ml) NS 29 0.00 0.77 0.18 −69.61 6.96 0.92
MM 29 26.58 83.51 19.44 −79.91 462.69 0.09
GR 29 85.51 150.53 35.03 −144.70 529.87 0.005
IL8 (pg/ml) NS 29 3328 20686 4814 −137069 51061 0.45
MM 29 51074 177356 41277 −331659 489670 0.41
GR 29 85702 156506 36424 −370412 1328885 0.004
IL10 (pg/ml) NS 29 0.00 0.46 0.11 −1.04 2.48 0.89
MM 29 1.80 4.80 1.12 −5.93 16.14 0.01
GR 29 3.03 6.63 1.54 −11.60 25.20 0.008
IL13 (pg/ml) NS 29 0.00 4.52 1.05 −87.11 116.31 0.97
MM 29 49.93 288.58 67.16 −1000.90 1080.11 0.09
GR 29 266.00 332.54 77.39 −466.57 908.99 0.001
IFN-γ (pg/ml) NS 29 0.00 0.00 0.00 −106.58 169.48 0.86
MM 29 1644.34 8456.16 1868.04 −30350.99 43924.50 0.15
GR 29 −165.66 1495.68 348.10 −6365.44 10243.64 0.36
Blend of L. acidophilus SD5221 and B. lactis SD5219 treatment
Allergen n n Median Rob. SD SE median Min. Max. p-value
IL5 (pg/ml) NS 31 0.00 0.83 0.19 −5.51 17.17 0.29
MM 31 0.23 77.11 17.36 −378.76 221.79 0.98
GR 31 29.36 170.38 38.35 −674.14 1686.96 0.20
IL8 (pg/ml) NS 31 2353 22598 5087 −240155 73699 0.84
MM 31 −26620 166240 37421 −353181 1134834 0.85
GR 31 −7132 153404 34532 −1326885 300638 0.96
IL10 (pg/ml) NS 31 0.00 0.41 0.09 −11.18 3.57 0.42
MM 31 0.84 6.02 1.36 −13.71 11.87 0.58
GR 31 0.60 5.95 1.34 −14.84 17.89 0.75
IL13 (pg/ml) NS 31 0.00 0.794 0.18 −10.672 70.676 0.04
MM 31 59.10 322.66 72.63 −1023.04 4155.62 0.42
GR 31 151.92 374.60 84 −721.54 924.79 0.14
IFN-γ (pg/ml) NS 31 0.00 0.46 0.10 −60.03 252.65 0.41
MM 31 −365.81 9372.17 2109.69 −45256.46 21604.04 0.59
GR 31 −200.91 1261.78 284.03 −8287.66 3864.57 0.59
Samples were collected 24 hours after NPT (post- minus pre-treatment differences; ITT data set). NS: non stimulated PBMCs; MM: PBMCs stimulated with vaccine
antigens cocktail; GR: PBMCs stimulated with grass pollen (ITT analysis).
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subjects, as well as timing and duration of probiotic
supplementation and possibly with the challenging clinical
trial setting of nasal provocation testing.
Due to the clinical trial setting used (comparison of two
probiotics preparations), both investigators and subjects
(although blinded with regard to the probiotic prepar-
ation) were aware that the aim of the study was to test
probiotics, and thus a possible placebo effect cannot be
excluded. However, this possible placebo effect would havebeen similar in the two groups and thus did most likely
not impact on the difference in terms of beneficial effect
observed between the 2 groups.
These results strongly suggest an intrinsic effect of
L. paracasei NCC2461 treatment via yet undefined
mechanisms. We may postulate a role for specific TLR
engagement by uncharacterized TLR ligands from the
L. paracasei NCC2461 strain, leading to an effect that
was not apparent after treatment with the blend of L.
acidophilus ATCC SD5221 and B. lactis ATCC SD5219
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mainly concerns TLR2 and TLR4, responsible for the
generation of TH1 cytokines by PBMCs [38]. We cannot
exclude that the secretion of IL-10 might play a marked
anti-inflammatory role in vivo, thus contributing to limit
the expansion of the systemic TH2 subset [39], that in
turn would reduce local responses, i.e. nasal pruritus and
nasal mucosa inflammation. The increase in cytokine
secretion by PBMC or the enhanced serum IgE was
very limited and of doubtful clinical significance, and
furthermore expectable in patients with established al-
lergen specific TH2 T cell response. Moreover, variation
in cytokine production was not significantly different
when both treatments were compared, except for IL-8
production. The role of inducible regulatory T cells
[40] or of TH17 cells [41] has not been evaluated in
this study but is strongly suggested by the enhanced
production in IL-10 post NCC2461 treatment and would
certainly deserve attention in the future.
In conclusion, the results presented here reinforced the
promising data already obtained in a preliminary study
with L. paracasei NCC2461 consumption [23]. Altogether,
L. paracasei NCC2461 consumption was well tolerated
and showed a therapeutic potential. We have also evalu-
ated the clinical trial setting of nasal provocation tests
as a possible way to examine candidate probiotic strains
and feel that this methodology, routinely employed for
demonstrating efficacy of mainstream pharmaceutical
treatment, could offer the probiotic field flexibility in terms
of conducting efficacy clinical trials as the window period
of seasonal allergens (grass, birch pollen) is sometimes
rather short to conduct field trials. However, we foresee
a combined approach of nasal provocation testing and
field trials to validate the scientific findings observed in
either setting. Future seasonal clinical trials are then
warranted to confirm the beneficial effect of L. paracasei
NCC2461 consumption, including assessment of quality
of life, combined symptom and medications scores and
key immune biomarkers.Abbreviations
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